Paul McNally

16PUBLICATIONS
26CO-AUTHORS
Medical biotechnology diagnostics (incl. biosensors)Infant and child healthSystems physiologyEpidemiological methodsMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Jun 03, 2026
Oxygen-enhanced MRI and multiple breath washout with Short extension reveal cystic fibrosis lung disease progression despite triple modulator therapy.

|Mar 25, 2026
ENHANCE: a community partnership charting the evolution of early-life cystic fibrosis disease manifestations in a new era of management.

Don S Urquhart, Barry Linnane, Clare J Saunders

|Oct 31, 2025
Real-World Outcomes of Elexacaftor/Tezacaftor/Ivacaftor in Children with Cystic Fibrosis.

Lucy Perrem, Paul McNally

|Jun 02, 2025
Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children ≥6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study.

Claire Wainwright, Susanna A McColley, Paul McNally

|Feb 14, 2024
Reply to Dournes and Benlala: Hierarchical Computed Tomography Scoring Systems Cannot Discriminate Between Reversible Bronchiectasis and Mucus Plugs.

Paul McNally, Jane Davies, Pierluigi Ciet

|Sep 13, 2023
Improvement in Lung Clearance Index and Chest Computed Tomography Scores with Elexacaftor/Tezacaftor/Ivacaftor Treatment in People with Cystic Fibrosis Aged 12 Years and Older - The RECOVER Trial.

Paul McNally, Karen Lester, Gavin Stone

Pageof 3

Frequent Collaborators

2 joint publications

Seamas Donnelly

2 joint publications

Marcus A Mall

2 joint publications

Lucy Perrem

2 joint publications

Edward McKone